Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
15 08 2021
15 08 2021
Historique:
received:
11
12
2020
accepted:
08
02
2021
pubmed:
16
5
2021
medline:
9
11
2021
entrez:
15
5
2021
Statut:
ppublish
Résumé
Cryptococcosis remains a leading cause of meningitis and mortality among people living with HIV (PLHIV) worldwide. We sought to evaluate laboratory-based cryptococcal antigen (CrAg) reflex testing and a clinic-based point-of-care (POC) CrAg screening intervention for preventing meningitis and mortality among PLHIV in South Africa. We conducted a prospective pre-post intervention study of adults presenting for HIV testing in Umlazi township, South Africa, over a 6-year period (2013-2019). Participants were enrolled during 3 phases of CrAg testing: CrAg testing ordered by a clinician (clinician-directed testing, 2013-2015); routine laboratory-based CrAg reflex testing for blood samples with CD4 ≤100 cells/mm3 (laboratory reflex testing, 2015-2017); and a clinic-based intervention with POC CD4 testing and POC CrAg testing for PLHIV with CD4 ≤200 cells/mm3 with continued standard-of-care routine laboratory reflex testing among those with CD4 ≤100 cells/mm3 (clinic-based testing, 2017-2019). The laboratory and clinical teams performed serum CrAg by enzyme immunoassay and lateral flow assay (Immy Diagnostics, Norman, OK). We followed up participants for up to 14 months to compare associations between baseline CrAg positivity, antiretroviral therapy and fluconazole treatment initiation, and outcomes of cryptococcal meningitis, hospitalization, and mortality. Three thousand one hundred five (39.4%) of 7877 people screened were HIV-positive, of whom 908 had CD4 ≤200 cells/mm3 and were included in the analyses. Laboratory reflex and clinic-based testing increased CrAg screening (P < 0.001) and diagnosis of CrAg-positive PLHIV (P = 0.011). When compared with clinician-directed testing, clinic-based CrAg testing showed an increase in the number of PLHIV diagnosed with cryptococcal meningitis (4.5% vs. 1.5%; P = 0.059), initiation of fluconazole preemptive therapy (7.2% vs. 2.5%; P = 0.010), and initiation of antiretroviral therapy (96.8% vs. 91.3%; P = 0.012). Comparing clinic-based testing with laboratory reflex testing, there was no significant difference in the cumulative incidence of cryptococcal meningitis (4.5% vs. 4.1%; P = 0.836) or mortality (8.1% vs. 9.9%; P = 0.557). Laboratory reflex and clinic-based CrAg testing facilitated the diagnosis of HIV-associated cryptococcosis and fluconazole initiation but did not reduce cryptococcal meningitis or mortality. In this nonrandomized cohort, clinical outcomes were similar between laboratory reflex testing and clinic-based POC CrAg testing.
Identifiants
pubmed: 33990495
doi: 10.1097/QAI.0000000000002717
pii: 00126334-202108150-00013
pmc: PMC8263484
mid: NIHMS1697432
doi:
Substances chimiques
Antifungal Agents
0
Antigens, Fungal
0
Fluconazole
8VZV102JFY
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205-1213Subventions
Organisme : NIAID NIH HHS
ID : K23 AI108293
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI141036
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI060354
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI143351
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. Lancet Infect Dis. 2017;17:873–881.
Jarvis JN, Meintjes G, Williams A, et al. Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis. 2010;10:67.
French N, Gray K, Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS. 2002;16:1031–1038.
Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12:929–935.
Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment clinic in South Africa. Clin Infect Dis. 2009;48:856–862.
Mfinanga S, Chanda D, Kivuyo SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385:2173–2182.
Kapoor SW, Magambo KA, Kalluvya SE, et al. Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia. AIDS. 2015;29:2473–2478.
Letang E, Muller MC, Ntamatungiro AJ, et al. Cryptococcal antigenemia in immunocompromised HIV patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis. 2015;2:ofv046.
Pett SL, Haddow L, Nhema R, et al. CrAg status and effects on benefits from enhanced prophylaxis in the REALITY trial. Abstracts presented at Conference on Retroviruses and Opportunistic Infections, 2018; March 5, 2018; Boston, MA. Poster #784.
World Health Organization. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. Geneva, Switzerland: WHO; 2011.
World Health Organization. Guidelines for the Diagnosis, Prevention, and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. Geneva, Switzerland: World Health Organization; 2018.
Rajasingham R, Meya DB, Boulware DR. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr. 2012;59:e85–e91.
Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019–1023.
Rugemalila J, Maro VP, Kapanda G, et al. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross sectional study and evaluation of a point-of-care lateral flow assay. Trop Med Int Health. 2013;18:1075–1079.
Klausner JD, Chiller TV. Sensitivity and specificity of a new cryptococcal antigen lateral flow assay in serum and cerebrospinal fluid. MLO Med Lab Obs. 2013;45:16–20.
McMullan BJ, Halliday C, Sorrell TC, et al. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One. 2012;7:e49541.
Drain PK, Hong T, Krows M, et al. Validation of clinic-based cryptococcal antigen lateral flow assay screening in HIV-infected adults in South Africa. Sci Rep. 2019;9:2687.
Republic of South Africa Department of Health. The South African Antiretroviral Treatment Guidelines. 2017.
Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6:e012799.
Ford N, Shubber Z, Jarvis JN, et al. CD4 cell count threshold for cryptococcal antigen screening of HIV-infected individuals: a systematic review and meta-analysis. Clin Infect Dis. 2018;66(suppl 2):S152–S159.
Govender NP. Declining Incidence of HIV-Associated Cryptococcosis in South Africa, 2005-2015. Abstracts presented at Conference on Retroviruses and Opportunistic Infections, 2018; March 5, 2018; Boston, MA. Poster #789.
Beyene T, Woldeamanuel Y, Asrat D, et al. Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia. PLoS One. 2013;8:e75585.
Hansen J, Slechta ES, Gates-Hollingsworth MA, et al. Large-scale evaluation of the immune-mycologics lateral flow and enzyme-linked immunoassay for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin Vaccin Immunol. 2013;20:52–55.
Williams DA, Kiiza T, Kwizera R, et al. Evaluation of fingerstick cryptococcal antigen lateral flow assay in HIV-infected persons: a diagnostic accuracy study. Clin Infect Dis. 2015;61:464–467.
Temfack E, Kouanfack C, Mossiang L, et al. Cryptococcal antigen screening in asymptomatic HIV-infected antiretroviral naïve patients in Cameroon and evaluation of the new semi-quantitative Biosynex CryptoPS Test. Front Microbio. 2018;9:409.